A cholesterol drug startup with dual headquarters in Ann Arbor and France could be headed toward an initial public offering, according to a Bloomberg report.

Cerenis Therapeutics SA, which raised more than $65 million in venture capital in 2010, could be targeting an IPO, a Paris-based researcher told Bloomberg.

That comes after Cerenis CEO Jean-Louis Dasseux said in 2011 that "he may consider funding options including an IPO in 2013," the news agency reported.

The startup's most advanced therapy, a drug called CER-001, would treat acute coronary syndrome. Cerenis has several other treatments that would improve the body’s production of HDL cholesterol, which helps the body eliminate harmful lipids and plaque that can cause diseases.

Among the company's investors is Ann Arbor-based EDF Ventures.

Contact AnnArbor.com's Nathan Bomey at (734) 623-2587 or nathanbomey@annarbor.com. You can also follow him on Twitter or subscribe to AnnArbor.com's newsletters.